Proteon Therapeutics Inc. News Releases http://ir.proteontherapeutics.com/ Proteon Therapeutics Inc. News Releases en Proteon Therapeutics Announces First Quarter 2019 Financial Results http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-first-quarter-2019-financial WALTHAM, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended March 31, Wed, 08 May 2019 08:00:00 -0400 Proteon Therapeutics Inc. News Releases 8661 Proteon Therapeutics Announces Review of Potential Strategic Transactions http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-review-potential-strategic WALTHAM, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its plans to explore a range of strategic options to Mon, 15 Apr 2019 16:30:00 -0400 Proteon Therapeutics Inc. News Releases 8656 Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-top-line-results-phase-3-patency - Investigational Vonapanitase Did Not Meet Co-Primary Endpoints - WALTHAM, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today Thu, 28 Mar 2019 08:00:00 -0400 Proteon Therapeutics Inc. News Releases 8636 Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-fourth-quarter-and-full-year-2018 WALTHAM, Mass. , March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31, Wed, 13 Mar 2019 08:00:00 -0400 Proteon Therapeutics Inc. News Releases 8601 Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-present-cowen-and-company-39th-annual WALTHAM, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Cowen and Mon, 04 Mar 2019 16:30:00 -0500 Proteon Therapeutics Inc. News Releases 8591 Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-publication-results-phase-3 Results supported the design of ongoing pivotal study and FDA Breakthrough Therapy designation WALTHAM, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc.  (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with Thu, 24 Jan 2019 08:00:00 -0500 Proteon Therapeutics Inc. News Releases 8551 Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-present-stifel-2018-healthcare-conference WALTHAM, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Stifel 2018 Thu, 08 Nov 2018 07:45:00 -0500 Proteon Therapeutics Inc. News Releases 8481 Proteon Therapeutics Announces Third Quarter 2018 Financial Results http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-third-quarter-2018-financial WALTHAM, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, Wed, 07 Nov 2018 08:00:00 -0500 Proteon Therapeutics Inc. News Releases 8466 Proteon Therapeutics to Present at Two Upcoming Investor Conferences http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-present-two-upcoming-investor-conferences-2 WALTHAM, Mass. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present a corporate overview Wed, 29 Aug 2018 08:00:00 -0400 Proteon Therapeutics Inc. News Releases 8431 Proteon Therapeutics Announces Second Quarter 2018 Financial Results http://ir.proteontherapeutics.com/news-releases/news-release-details/proteon-therapeutics-announces-second-quarter-2018-financial WALTHAM, Mass. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June 30, 2018 Tue, 07 Aug 2018 08:00:00 -0400 Proteon Therapeutics Inc. News Releases 8416